A delegation of EMBL Australia researchers and senior administrators descended on the EMBL Heidelberg last month for a three-day program that included touring some of EMBL’s world-class core facilities, meeting international colleagues and sharing ideas for the direction of future research in a joint scientific symposium.

Dr Richard Morris will join our Partner Laboratory Network as a Group Leader, based at the University of New South Wales, early next year.

The mystery of what causes Alzheimer’s disease is a step closer to being solved thanks to an EMBL Australia group leader and his team, who have revealed a genetic link between Alzheimer’s and the endo-lysosomal system, a critical part of biological recycling machinery that maintains the health of brain cells. 

EMBL Australia Scientific Head Professor James Whisstock was today awarded an Australian Research Council Australian Laureate Fellowship.

EMBL Director General Professor Iain Mattaj shares how his institution’s unique model of giving the most talented young researchers scientific freedom has led to ground-breaking discoveries.

Students awarded EMBL Australia travel grants say their international trips led to postdoctoral job offers and enhanced their research, networks and collaboration opportunities.

The Australian National University has joined our Partner Laboratory Network as our first host institute in the ACT. 

Chief Scientist Dr Alan Finkel, EMBL Director General Prof Iain Mattaj and EMBL Australia Scientific Head Prof James Whisstock were some of the esteemed speakers to present at the node launch event on
14 June.

Dr Robert Weatheritt is an EMBL Australia Group Leader, based at the Garvan Institute of Medical Research, Sydney.

Research led by EMBL Australia Group Leader David Lynn has shown that, in preclinical animal models, antibiotic exposure in infants impairs their immune responses to five important, routine vaccinations that are administered worldwide - including vaccines against meningitis, pneumonia, tuberculosis and whooping cough. The research was published Cell Host & Microbe.

Dr Harald Janovjak has been awarded a JDRF project grant for his innovative work using light as a new strategy to treat type 1 diabetes. The EMBL Australia Group Leader’s work is the first application of visible light treatment to the insulin-making beta cells that are destroyed in type 1 diabetics.